Phaseline

Targets › FAS

FAS (Tumor necrosis factor receptor superfamily member 6): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Ophthalmology; next expected readout Nov 2028.

Receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase CASP8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs CASP8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. (UniProt, P25445)

Open in Phaseline: the race on FAS, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
ONL TherapeuticsONL1204 Ophthalmic Solution
Fragment apoptosis stimulator (FAS) receptor inhibitor
FASPhase 2Geographic Atrophy (GA)Nov 2028

Conditions

Geographic Atrophy (GA) (1)

Modalities

small molecule (1)

Companies

ONL Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.